Disclosure of Unapproved or Investigational Use of Products or Devices

• Jay Allen, MD, made a disclosure of Unapproved or Investigational Use of Products or Devices for his presentation GLP-1 Agonists: A New Frontier in Medicine. Discussion will include emerging evidence regarding GLP-1 agonists, including for alcohol use disorder and knee osteoarthritis. These uses are not FDA approved.
• Hannah Elsenpeter, MD, has made a disclosure of Unapproved or Investigational Use of Products or Devices for her presentation Skin through the Lifespan: Common Concerns and Practical Pointers. Discussion will include use of ivermectin (off-label) for demodex folliculitis.
• Britta Reierson, MD, FAAFP, DABOM, made a disclosure of Unapproved or Investigational Use of Products or Devices for her presentation Transforming Obesity Care: Innovative Approaches for Family Physicians. Discussion will include medications in the pipeline that are currently in medication trials and not yet FDA approved, off-label use of medications for obesity such as metformin, and individual medication components of Qsymia (phentermine, topiramate) and Contrave (bupropion, naltrexone).
• Barbara Yawn, MD, MSc, made a disclosure of Unapproved or Investigational Use of Products or Devices for her presentation Updates for Asthma Management. Discussion will include data on the use of budesonide/formoterol and mometasone/formoterol as SMART therapy meaning as both maintenance and quick reliever. This is not FDA approved but is recommended by the international GINA guidelines and has been shown to be safe and effective in several U.S.-based studies (data will be presented) and is the standard of care in most European countries and Australia.